Compositions and methods relating to DENND1A variant 2 and polycystic ovary syndrome

A method for selecting an individual as a candidate for therapy for polycystic ovary syndrome, the method comprising the steps of:

• measuring an amount of DENND1A Variant 2 protein in a biological sample from said individual, wherein measuring the DENND1A Variant 2 protein is performed using a composition comprising antibodies, wherein the antibodies are hybridized bound to the DENND1A Variant 2 protein, wherein the binding of the antibodies to the DENND1A Variant 2 protein is detected, and wherein the antibodies specifically recognize at least one epitope in a segment of the DENND1A Variant 2 protein consisting of the 33 amino acids at its C-terminus, wherein the DENND1A Variant 2 protein is contacted with the antibodies and wherein antibodies bound to the segment are detected;
• diagnosing said individual with polycystic ovary syndrome when said amount of DENND1A Variant 2 protein is increased as compared to the reference value;
• and
• designating the individual diagnosed with polycystic ovary syndrome as a candidate for the polycystic ovary syndrome therapy.